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Aims Hypertension is common. Recent data suggest that macrophages (M/) contribute to, and protect from, hyperten-
sion. Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor with additional pro-inflammatory proper-
ties. We investigated the role of the ET system in experimental and clinical hypertension by modifying M/ number
and phenotype.
...................................................................................................................................................................................................
Methods
and results
In vitro, M/ ET receptor function was explored using pharmacological, gene silencing, and knockout approaches.
Using the CD11b-DTR mouse and novel mice with myeloid cell-specific endothelin-B (ETB) receptor deficiency
(LysMETB
-/-), we explored the effects of modifying M/ number and phenotype on the hypertensive effects of ET-1,
angiotensin II (ANG II), a model that is ET-1 dependent, and salt. In patients with small vessel vasculitis, the impacts
of M/ depleting and non-depleting therapies on blood pressure (BP) and endothelial function were examined.
Mouse and human M/ expressed both endothelin-A and ETB receptors and displayed chemokinesis to ET-1.
However, stimulation of M/ with exogenous ET-1 did not polarize M/ phenotype. Interestingly, both mouse and
human M/ cleared ET-1 through ETB receptor mediated, and dynamin-dependent, endocytosis. M/ depletion
resulted in an augmented chronic hypertensive response to both ET-1 and salt. LysMETB
-/- mice displayed an exag-
gerated hypertensive response to both ET-1 and ANG II. Finally, in patients who received M/ depleting immuno-
therapy BP was higher and endothelial function worse than in those receiving non-depleting therapies.
...................................................................................................................................................................................................
Conclusion M/ and ET-1 may play an important role in BP control and potentially have a critical role as a therapeutic target in
hypertension.
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Introduction
Arterial hypertension is a major risk factor for atherosclerosis, coron-
ary artery disease, stroke, and chronic kidney disease, and is a
prominent contributor to death worldwide.1 It is estimated that a
quarter of the world’s adult population is hypertensive and this num-
ber is projected to rise to nearly 30% by 2025.2 By age 70 years, 70%
of the US population have hypertension. However, despite the
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..frequency of hypertension, its cause in the majority of adults is
unknown.
Hypertension is complex, with no single mechanism—sodium re-
tention, renin release, and increased vascular tone—entirely explain-
ing the blood pressure (BP) rise. The past 50 years have seen growing
evidence implicating the immune system.3 Recent data suggest that
macrophages (M/) contribute to, and protect from, hypertension.
Early studies in the spontaneously hypertensive rat4 found a correl-
ation between the distribution of sub-endothelial M/ and endothelial
function, and that treatment with an angiotensin converting enzyme
inhibitor improved endothelial function and reduced the number of
vascular M/. Furthermore, many models of hypertension—angioten-
sin II (ANG II), high salt—are associated with renal accumulation of
M/.5,6 Despite these and many other observational studies, few have
attempted to modify M/ phenotype/number to examine their role in
hypertension.7–10
Endothelin-1 (ET-1) is the most potent endogenous vasocon-
strictor.11 Its production is triggered by multiple stimuli includ-
ing ANG II and pro-inflammatory cytokines.12,13 ET-1 acts by
binding to two distinct receptors, the endothelin-A (ETA) and
the endothelin-B (ETB) receptors.
14,15 ETA and ETB receptors
on vascular smooth muscle cell (VSMC) mediate the vasocon-
strictor effects of ET-1.16 ETB receptors are also found on vas-
cular endothelial cells (EC) where their activation results in
dilation.17,18 Production of vascular ET-1 is increased in some
but not all animal models of hypertension.19 Interestingly, ET
antagonism can blunt BP elevation in ANG II infused rats sug-
gesting that in this model, ET-1 largely mediates the hyperten-
sive effects of ANG II.20,21 Importantly, a number of clinical
studies have gone on to show the effectiveness of both select-
ive ETA and mixed ETA/B antagonism in lowering BP in hyper-
tension.22–24
ET-1 is considered to be pro-inflammatory. ETA receptor activa-
tion is crucial in mediating the ANG II-induced infiltration of renal
cortical T cells.25 In both models of aldosterone-induced hyperten-
sion and diabetic nephropathy, selective ETA receptor antagonism
reduced M/ infiltration,26,27 and in the diabetic model also reduced
fibrosis.27 However, the effects of ET-1 on M/ biology are not well
studied. In the current studies, we explored the role of M/ and
monocytes in mediating the pro-hypertensive effects of ET-1 and
ANG II.
Methods
See Supplementary material online.
Results
Macrophages possess endothelin
receptors but are not polarized by
endothelin-1
We first found that mouse bone marrow-derived macrophages
(BMDM) possess both ETA and ETB receptors (ETB > ETA) although
in relatively lower amounts than seen in VSMC and EC, respectively
(see Supplementary material online, Figure S1). To examine the role
of the M/ ETB receptor in greater detail, we generated novel mice
deficient in ETB on myeloid cells alone (LysMETB
-/-). These mice
showed no differences in baseline vascular function or circulating im-
mune cells compared with littermate controls (see Figure 1 and
Supplementary material online, Figures S2–S4).
We then explored the ability of ET-1 to polarize BMDM.
Increasing concentrations of ET-1 (10–104 pg/mL) were unable to
polarize BMDM to a classical (M1) or alternative (M2) phenotype ei-
ther alone or in combination (see Figure 2 and Supplementary mater-
ial online, Figure S5). Furthermore, neither co-stimulation with LPS
and ET-1 nor LPS stimulation following ET-1 priming, in the presence
or absence of ET receptor blockade, augmented the BMDM re-
sponse to LPS (see Supplementary material online, Figure S6).
BMDM stimulation with LPS/INFc (but not IL-4/IL-13)
increased the media concentration of ET-1 at 24 h (see
Supplementary material online, Figure S7), an effect that was
blocked by phosphoramidon, an inhibitor of endothelin convert-
ing enzyme (ECE) which catalyzes the conversion of big ET-1 to
the mature peptide. Thus, this increase in ET-1 likely represents
de novo production.
Macrophages demonstrate chemokinesis
to endothelin-1
Despite the lack of polarization by ET-1, BMDM demonstrated che-
mokinesis to ET-1. This effect was more apparent at higher concen-
trations of ET-1 and no different to MCP-1 at ET-1 103 pg/mL and
104 pg/mL. BMDM chemokinesis to ET-1 was blocked by both
Translational perspective
Hypertension is a costly global health problem, and an important risk factor for the development and progression of chronic
kidney disease. Its aetiology remains unclear in most adults. Here, the data provided suggest that the immune and endothelin
systems play important roles in blood pressure regulation and provide a rational basis for further investigation into the
modulation of these pathways. These studies may encourage industry to take a lead in this relatively orphan area, potentially
resulting in a more rational prescribing of endothelin receptor antagonists for hypertension that has developed as part of a
multi-system inflammatory disease, with these agents potentially affording broader cardiovascular protection. These studies
may also help inform the design of novel antihypertensive therapies.
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.selective ETA (BQ123) and selective ETB (BQ788) receptor antagon-
ism (Figure 3A). In terms of chemokinetic ability, LysMETB
-/- BMDM
had a blunted response to incremental concentrations of ET-1 com-
pared with control BMDM, although the response to MCP-1 was
maintained (Figure 3B).
Macrophages demonstrate endothelin-B-
mediated endothelin-1 uptake
BMDM were then exposed to ET-1 10 pg/mL in their media. Serial
assay of the media for ET-1 showed a gradual reduction over a 24 h
period with the concentration at 24 h being approximately 60% that at
baseline (Figure 4A). This reduction in media ET-1 was seen when
BMDM were exposed to increasing concentrations of ET-1 (Figure 4B)
and was not explained by degradation of the peptide over the 24 h
period (see Supplementary material online, Figure S8). The fall in ET-1
was prevented by both selective antagonism of the ETB receptor (but
not ETA) as well as inhibition of dynamin-dependent endocytosis (see
Figure 4C and Supplementary material online, Figure S9), supporting
BMDM uptake of ET-1 through ETB receptor-mediated endocytosis.
Neutral endopeptidase (NEP) inhibition had no effect. Additionally,
mixed ETA/B receptor antagonism was no different to selective ETB
blockade alone (see Supplementary material online, Figure S10).
Further data to support the role of the M/ ETB receptor in clear-
ing ET-1 were provided using an ETB gene silencing approach. M/
EDNRB knockdown again prevented ET-1 uptake by BMDM, an effect
that was similar in magnitude to that seen with pharmacological ETB
receptor antagonism (Figure 4D). As ETB receptors are also present
on VSMC, we assessed their ability to remove ET-1 in vitro. VSMC did
not remove ET-1 from their surrounding media (Figure 4E). BMDM
from LysMETB
-/- and controls were also exposed to ET-1 for 24 h. As
previously seen, control BMDM removed ET-1 from their medium,
an effect that was blocked by BQ788. Medium from LysMETB
-/-
BMDM showed no difference in ET-1 concentration at 24 h com-
pared with baseline and there was no effect of pre-treatment with
BQ788 (Figure 4F). To further support our hypothesis of M/ ET-1
uptake, we exposed BMDM to fluorescent ET-1. Our results sug-
gested a statistically significant (P< 0.01) increase in BMDM intra-
cellular fluorescence following treatment with ET-1 (Figure 4G).
Uptake of fluorescence was blocked by selective blockade of the
ETB receptor and absent, as expected, in BMDM from LysMETB
-/-
mice. Furthermore, this uptake process occurred rapidly
(Figure 4H) and reached a steady state within 60 min.
Macrophages modify vascular
contractility
The functional importance of M/ ETB receptor-mediated ET-1 up-
take is demonstrated in Figure 5. Here, we infused M/ into the myog-
raphy bath 15 min prior to infusing ET-1. Increasing number of M/
significantly attenuated the vasoconstrictor actions of ET-1 (P< 0.001
vs. control); this effect was lost when the M/ were pre-treated with
selective ETB receptor antagonism or when LysMETB
-/- BMDM were
infused. There was no effect of pre-treating M/ with a selective ETA
receptor antagonist. M/ pre-treatment did not alter the contractile
response to KCl. Again, these findings are in keeping with a rapid
binding of ET-1 to M/ ETB that blunts its functional effects.
Additionally, and as expected, ET-1 increased oxidative stress in mes-
enteric vessels; this effect was attenuated by M/ and attenuation was
dependent on an unblocked ETB receptor.
Figure 1 Characterization of the endothelin system in LysMETB
-/-. (A) qRT-PCR analysis of EDNRB (endothelin-B), EDNRA (endothelin-A), and
EDN1 (endothelin-1) expression in bone marrow-derived M/. (B) EDNRB (endothelin-B) expression in peritoneal M/ (left panel), bone marrow-
derived M/, T and B cells (middle panel), and plasma endothelin-1 (right panel). Data are expressed as mean ± standard deviation and comparisons
were made with unpaired t-tests and for (B) middle panel, Holm–Sidak was used to correct for multiple comparisons; adjusted P-values are shown.
Myeloid endothelin-B receptors in hypertension 3
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..Human and mouse macrophages show
similar responses to endothelin-1
As in mouse BMDM, human M/ showed expression of both the
ETA and ETB receptor (see Supplementary material online,
Figure 11A). Similarly, human M/ were not polarized to a
classical or alternative phenotype by ET-1 (see Supplementary
material online, Table S1 and Figure S11B) but showed
evidence of ETB receptor-mediated ET-1 uptake and
Figure 2 In vitro stimulation with endothelin-1 does not polarize M/ to a classical or alternative phenotype. (A) Bone marrow-derived M/ produc-
tion of TNFa, IL-6, and IL-10 after 24 h stimulation with endothelin-1 (10–104 pg/mL), LPS/INFc, IL-4/IL-13, and in untreated controls. Data (mean-
± standard deviation; n= 4 per group) were compared by two-way analysis of variance, with main effects of treatment (P< 0.0001), production
(P= 0.186), and the interaction (P= 0.0006). Multiple comparisons were made to compare the effect of each treatment against control (media alone),
with a family P-value of 0.01; an adjusted P-value is shown. (B) Bone marrow-derived M/ mRNA production of a range of M1 (left) and M2 (right)
markers following 24 h stimulation with endothelin-1 (10 pg/mL and 104 pg/mL). Data (mean ± standard deviation; n= 4 per group) were compared
by two-way analysis of variance (main effects of treatment, of gene product and the interaction were all P< 0.0001). Multiple comparisons were
made to compare the effect of each treatment on mRNA production against control (media), with a family P-value of 0.01. Adjusted P-values are
shown. (C) Western blot analysis demonstrating endothelin-1, either alone or in combination with LPS/INFc, did not stimulate production of caspase
1 in mouse M/. (D) Endothelin-1 alone (media) or in combination with LPS/INFc, did not stimulate production of IL-1b by mouse M/.
4 A. Czopek et al.
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.chemokinesis to ET-1 and (see Supplementary material online,
Figure S11C and D).
Macrophage depletion augments the
pressor response to endothelin-1 but
not angiotensin II
To understand the role of M/ in the pressor response to ET-1,
we administered incremental doses of intravenous (i.v.) ET-1 to
CD11b-DTR mice given diphtheria toxin (DT) and to controls. M/
depletion per se was not associated with a difference in baseline mean
arterial pressure (MAP) (Figure 6A) or a shift in vasoconstrictor-
vasodilator capacity of conduit or resistance vessels (see
Supplementary material online, Figure S12). Administration of ET-1
following M/ depletion resulted in an exaggerated hypertensive re-
sponse compared with controls (Figure 6B) with a greater maximal
change in mean arterial pressure (MAP) in M/-deficient mice
(Figure 6C). At a dose of ET-1 1 nmol/kg the maximal change in MAP
Figure 3 Macrophage demonstrate chemokinesis towards endothelin-1. (A) Bone marrow-derived M/ chemokinesis in response to increasing
doses of endothelin-1 in the presence or absence of selective endothelin-A (BQ123) or endothelin-B (BQ788) antagonism; MCP-1 was used as a
positive control. The number of M/ per high powered field (mean ± standard deviation; n= 6 mice per group) was compared by two-way analysis of
variance, with main effects of endothelin-1 or MCP-1 treatment (P< 0.0001) and receptor antagonism (P< 0.0001) and the interaction (P< 0.0001).
Effects within rows were compared, using one family per row and a family P-value of 0.01. Adjusted P-values are shown. (B) Chemokinesis of bone
marrow-derived M/ in response to endothelin-1 or MCP-1. Bone marrow-derived M/ were isolated from LysMETB
-/- (open circles; n= 6) and con-
trol (closed circles; n= 6) mice. Data were compared by two-way analysis of variance, with main effects of endothelin-1 or MCP-1 treatment
(P< 0.0001) and genotype (P< 0.0001) and the interaction (P< 0.0001). Between genotype comparisons were made and adjusted P-values are
shown.
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Figure 4 Macrophages clear endothelin-1 through endothelin-B receptor-mediated endocytosis. Endothelin-1 concentration in cell culture super-
natant from bone marrow-derived M/ (A) over 24 h after incubation with a starting endothelin-1 concentration of 10 pg/mL, (B) at 24 h following in-
cubation with endothelin-1 (10–104 pg/mL), (C) after incubation with an endothelin-A (BQ123) or endothelin-B (BQ788) antagonist or dynasore, an
inhibitor of dynamin-dependent endocytosis receptor antagonism, and (D) following bone marrow-derived M/ endothelin-B receptor knockdown
with siRNA (efficiency of knockdown left panel). Kruskal–Wallis tests were used with Dunn’s test for multiple planned comparisons. Adjusted P-val-
ues are shown. For (D) left panel an unpaired t-test was used; the two-tailed P-value is shown.
Continued
6 A. Czopek et al.
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Figure 4 (E) Vascular smooth muscle cells do not remove endothelin-1 from their media in vitro. Data from individual experiments are shown and
were compared by Kruskal–Wallis; with Dunn’s test for multiple planned comparisons as shown. (F) Wild type (white circles) and LysMETB
-/- (black
circles) bone marrow-derived M/ were exposed to endothelin-1 10 pg/mL in vitro in the presence or absence of BQ788, an endothelin-B receptor
antagonist. Endothelin-1 was measured in the supernatant at 24 h. One-way analysis of variance (P= 0.0003) was used and adjusted P-values for mul-
tiple comparisons are shown. (G) Uptake of fluorescent endothelin-1 by wild type or LysMETB
-/- bone marrow-derived M/ in the presence or ab-
sence of BQ788. One-way analysis of variance (P< 0.0001) was used and adjusted P-values for planned comparisons, as shown. (H) Rapid uptake of
endothelin-1 by bone marrow-derived M/.
Myeloid endothelin-B receptors in hypertension 7
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Figure 5 Macrophages modify vascular contraction and oxidative stress in response to endothelin-1. (A) Contraction of mesenteric artery seg-
ments to increasing (endothelin-1) (Control, black line, n= 10) and following pre-incubation with varying number of M/ (n= 6 per group). (B)
Vascular responses to 107 M/ (red line, n= 6), M/ þ BQ123 (dotted red line, n= 4), M/ from LysMETB-/- mice (blue line, n= 4), and M/ þ BQ788
(dotted blue line, n= 6). Data (mean ± standard deviation) were compared by two-way analysis of variance, with main effects of endothelin-1, pre-
treatment and the interaction (all P < 0.0001). Adjusted P-values for planned comparisons are shown and only the comparisons where P < 0.05 at
107 endothelin-1 are shown. (C) The effects of M/ on oxidative stress. Mean ± standard deviation were compared by one-way analysis of variance
(P= 0.0002), using Sidak correction for multiple comparisons, with adjusted P-values are shown.
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was approximately two-fold greater in M/ deficient mice compared
with control groups. Notably, M/ depletion did not affect the acute
pressor response to ANG II (Figure 6D).
To specifically explore the role of the M/ ETB receptor in the
pressor response to ET-1, we administered i.v. ET-1 to LysMETB
-/-
and control mice. Baseline MAP did not differ between the two
groups (Figure 6E). Similar to the response seen following systemic
M/ depletion, LysMETB
-/- mice demonstrated an exaggerated pressor
response to ET-1 (Figure 6F). At a dose of ET-1 0.1 nmol/kg the max-
imal change in MAP was approximately two-fold that seen in control
animals.
Macrophage depletion augments the
chronic hypertensive response to
endothelin-1 and adoptive transfer of
wild type monocytes prevents this
A 3-week infusion of ET-1 led to sustained increases in systolic and
diastolic BP in CD11b-DTR mice (Figure 7A and B). Both systolic and
diastolic BP increased by approximately 10–12 mmHg above base-
line. DT was used to deplete M/ over a period of 7–10 days resulting
in gradual increases in both systolic and diastolic BP (Figure 7C and D).
As the effects of DT weaned, and M/ repopulated, BP gradually
returned to pre-depletion levels. The maximal increase in systolic BP
was approximately 20 mmHg and for diastolic BP this was approxi-
mately 15 mmHg. In the negative control arm, CD11b-DTR mice
were injected with phosphate buffered saline, and here, BP remained
stable throughout the experiment.
In keeping with an important role for circulating monocytes in
these effects, adoptive transfer of wild type monocytes prevented
the rise in BP seen with DT (Figure 7E and F). As might be expected,
M/ depletion was associated with a rise in circulating ET-1 with a fall
to pre-depletion levels with M/ repopulation (Figure 7G).
Macrophage depletion augments the
chronic hypertensive response to a high
salt diet
Next, we explored the role of M/ in a second model of hypertension
that associated with a high salt diet. High salt led to rises in both sys-
tolic and diastolic BP of approximately 10 mmHg above baseline (see
Supplementary material online, Figure S13A). M/ depletion led to fur-
ther rises in both and, as previously seen, these effects diminished
with M/ repopulation (see Supplementary material online, Figure
S13B and C).
Myeloid ETB receptor deficiency
augments the chronic hypertensive
response to endothelin-1 and
angiotensin II
In line with an important role for the myeloid ETB receptor in pro-
tecting from the deleterious effects of ET-1, ET-1 administration into
LysMETB
-/- mice led to a two- to three-fold exaggerated hypertensive
response to ET-1 compared with littermate control mice (Figure 8A).
To confirm our findings, we exposed LysMETB
-/- and littermate con-
trol mice to a 2-week infusion of ANG II, a model of hypertension
that is ET-1 dependent.20,21 Baseline systolic and diastolic BP were
similar between the two groups of animals during both the active
(night) and inactive (day) phases. LysMETB
-/- mice had a significantly
exaggerated hypertensive response to ANG II compared with their
controls. For example, at night, systolic BP rose on average by ap-
proximately 25 mmHg in control mice but by approximately
40 mmHg in knockouts. For diastolic BP, these corresponding figures
were approximately 25 mmHg and approximately 35 mmHg
(Figure 8B).
In patients with anti-neutrophil
cytoplasmic antibody vasculitis different
immunotherapies variably affect blood
pressure and the endothelin system
Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are
standard therapies for patients with small vessel vasculitis associated
with autoantibodies to neutrophil cytoplasmic antigens (ANCA).
Cyclophosphamide not only depletes B and T cells but also effectively
depletes circulating and tissue M/28; MMF suppresses T- and B-cell
function but does not deplete M/. Thus, we investigated changes in
BP and the ET system following treatment in 20 patients with ANCA
vasculitis: 10 received CYC as their immunosuppressive therapy
whereas the other 10 received MMF. Demographics and other treat-
ments, including corticosteroid dose, antihypertensive treatment,
and the use of plasmapharesis, were similar between groups (see
Supplementary material online, Table S2).
Baseline systolic and diastolic BP, plasma and urine ET-1 did not dif-
fer between the two groups (see Supplementary material online,
Table S2). Interestingly, plasma ET-1 was higher in patients with
ANCA vasculitis than in healthy volunteers (3.74 ± 0.38 pg/mL vs.
1.21 ± 1.2 pg/mL, P= 0.02). Whereas CYC reduced mean circulating
monocyte count MMF did not (baseline vs. week 6: CYC: 0.87± 0.15
vs. 0.26 ± 0.17 109, P< 0.05; MMF: 0.77 ± 0.25 vs. 0.69± 0.29 109,
P= 0.756). Cyclophosphamide treatment was associated with a
greater increase in BP compared with treatment with MMF (Figure 9A
and B, P< 0.01 for CYC vs. MMF). There was a positive correlation
between the change in peripheral monocyte count and the extent to
which BP rose in those patients receiving CYC (Figure 9C and D).
Plasma ET-1 fell following treatment with MMF (Figure 9E, P< 0.001
for both weeks 0 vs. 6 and 6 vs. 12), whereas CYC treatment only led
to an initial fall in plasma ET-1 (P< 0.05 for weeks 0 vs. 6). Plasma ET-
1 was lower at week 12 in those treated with MMF (Figure 9E). Urine
ET-1 fell with both CYC and MMF (Figure 9F, P< 0.01 for CYC and
P< 0.0001 for MMF for weeks 0 vs. 12) but to a greater degree with
MMF (P< 0.01 for MMF vs. CYC). Flow-mediated dilation (FMD) of
the brachial artery was similar at baseline between the two groups
(6.7± 0.2 for MMF vs. 6.6± 0.1% for CYC, P= 0.589). At 12 weeks,
FMD had not changed in those patients receiving MMF treatment)
whereas those patients receiving CYC had lower FMD in keeping
with worse endothelial function (-1.2%, P< 0.05 vs. baseline).
In these same patients, we characterized M/ expression of ETA
and ETB receptors and compared this to health (see Supplementary
material online, Table S2 and Figure S9G and H). There were no differ-
ences in expression of the ETA receptor between the groups and in
keeping with our previous data its expression was lower than that of
the ETB receptor. Interestingly, patients presenting with ANCA vas-
culitis demonstrated reduced expression of the ETB receptor on
Myeloid endothelin-B receptors in hypertension 9
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Figure 6 Role of M/ in the pressor response to endothelin-1. Acute blood pressure response to incremental doses of endothelin-1 following
acute depletion of circulating monocytes and resident M/ (DTRþDTþ), and in controls [those with the diphtheria toxin receptor (DTR) construct
but given saline, DTRþDT-, and mice given diphtheria toxin (DT), DTR-DTþ; n= 10 mice/group]. (A) Baseline blood pressure. (B) Example of the
differences seen among the three groups in the acute pressor response to endothelin-1. Intravenous endothelin-1 administration is defined by the
black arrow. The dotted and dashed lines represent baseline and maximal mean arterial pressure, respectively. (C) Maximal change in mean arterial
pressure, compared by two-way analysis of variance (main effect of genotype, of endothelin-1 dose and the interaction all P= 0.0001); Holm–Sidak
planned comparisons were made and adjusted P-values are shown. (D) Acute blood pressure response to ANG II (1 nmol/kg) following
depletion of circulating monocytes and resident M/. (E) Baseline mean arterial pressure and (F) maximal change in mean arterial pressure in
response to endothelin-1 in LysMETB
-/- and littermate control mice (n= 6 mice per group), compared by two-way analysis of variance
[main effect of genotype P= 0.0128, of endothelin-1 dose (P= 0.0001) and the interaction P= 0.0004]; Holm–Sidak planned comparisons
were made and adjusted P-values are shown.
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Figure 7 Effects of chronic M/ depletion on endothelin-1-mediated hypertension. Effects on systolic and diastolic blood pressure of endothelin-1
infusion (10 pmol/kg/min administered via minipump) for 3 weeks (mean ± standard deviation, n= 12 mice, A and B). From Day 21, half the mice
(n= 6) underwent M/ depletion over the period shown in grey. Groups were compared by two-away analysis of variance, assessing the main effect
of M/ depletion, duration in days and the interaction. The effect of M/ depletion was P< 0.0001 for (C) systolic blood pressure and (D) diastolic
blood pressure. Effects of diphtheria toxin alone or diphtheria toxin with adoptive transfer of CD11bþGr1þmonocytes at Day 21 and Day 24 on sys-
tolic and diastolic blood pressure are shown in (E) and (F). Two-way analysis of variance reported a significant (P= 0.0003) effect of group. (G) The
effects of M/ depletion and repopulation on plasma endothelin-1 (n= 5 mice per group), assessed by one-way analysis of variance (P< 0.0001), with
the adjusted P-values for planned comparisons are shown.
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Figure 8 Effects of myeloid endothelin-B receptor deficiency on endothelin-1 and angiotensin II-mediated hypertension. Night-time and daytime
telemetry systolic and diastolic blood pressure in LysMETB
-/- and wild type controls receiving 2 weeks of endothelin-1 (5 pmol/kg/min; n= 8 mice per
group) (A) or angiotensin II (1mg/kg/min; n= 12 mice/group) (B). Data are mean ± standard deviation and two-way analysis of variance compared the
main effects of genotype, treatment (endothelin-1 or angiotensin II) and the interaction. In all cases, there was a significant (P<0.0001) effect of
genotype.
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Figure 9 Effects of treatment with cyclophosphamide and mycophenolate mofetil in patients with autoantibodies to neutrophil cytoplasmic anti-
gens vasculitis. (A and B) Systolic and diastolic blood pressure, with two-way analysis of variance showing a significant effect of treatment (P= 0.001).
(C and D) The relationship between change in circulating monocyte count and changes in systolic and diastolic blood pressure is shown. (E) Plasma
endothelin-1 (effect of treatment P= 0.0225) and (F) urine endothelin-1 (effect of treatment P= 0.2053). (G andH) Monocyte expression of endothe-
lin-A (P= 0.1310) and endothelin-B receptors (P= 0.0001) in patients with autoantibodies to neutrophil cytoplasmic antigens vasculitis, compared by
one-way analysis of variance with adjusted P-values are shown.
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.their M/ compared with levels seen in health. This was normalized
by treatment with MMF but further reduced following treatment
with CYC.
Discussion
For the first time, we have demonstrated that the M/ ETB receptor
in both mouse and humans provides a novel clearance mechanism
for ET-1. Its functional importance in vivo is demonstrated by the
exaggerated pro-hypertensive effect of ET-1 and ANG II in mice with
a deletion of the M/ ETB receptor or following systemic M/ deple-
tion. Interestingly, and unexpectedly, we found no evidence that ET-1
was able to polarize mouse or human M/ towards a classical pro-
inflammatory or alternative anti-inflammatory phenotype but both
displayed chemokinesis towards ET-1. Overall, these data provide us
with new knowledge, and a clarification of mechanisms underlying
the pathological basis of hypertension in relation to the immune and
ET systems (Figure 10).
To date, many of the studies investigating the role of the innate im-
mune system in the pathogenesis of, and response to, hypertension
have focused on the role of T cells in relation to ANG II-mediated
hypertension.29–31 Few have examined the role of M/ and only one
study relates to ET-1-mediated vascular injury.32 Recent studies have
explored the effects of altering the phenotype of bone marrow-
derived cells9 or M/10 on hypertension and its complications, where-
as others have elegantly depleted neutrophils and M/8 to this end.
The results of these studies are often contradictory but, nevertheless,
suggest that M/ may contribute to, and protect from, hypertension.
The study by Machnik et al.7 showed that salt loading increases M/
accumulation in the subcutaneous space. These M/ are stimulated
by the hypertonic environment to produce vascular endothelial
growth factor C. This leads to proliferation of lymphatics. This is pro-
tective, because clodronate-mediated M/ depletion prevents the
lymphatic proliferation and leads to hypertension in response to salt
loading. These landmark findings support a role for M/ acting as a
buffering mechanism, protecting against the development of hyper-
tension. Our study extends beyond these, providing a mechanistic
understanding of the interaction between M/ and local vascular con-
tractility and the impact on BP.
The M/ system comprises a spectrum of cell types, and depletion
strategies vary in their specificity and efficacy.33 Hence, we used two
depletion models here, the CD11b-DTR (reduction in M/ number)
and lysozyme M (LysM; alternation in M/ phenotype)-Cre systems.
DT administration on CD11b-DTR mice achieved 90% ablation
of circulating monocytes. In terms of resident cells, there was a
significant reduction in renal M/ but less of an effect in the liver and
spleen. Analysis of the main monocyte subsets (Gr11 CCR21
CX3CR12 and Gr12 CCR22 CX3CR11) demonstrated that
both are equally depleted over the time course of our studies. DT
administration did not deplete neutrophils. These findings are in
keeping with earlier studies.34,35 Using the LysM-Cre system, there is
functional depletion (80–100%) of mature M/ but also neutrophils.
Figure 10 Macrophage-endothelin system interplay. Endothelin-1 is produced predominantly by vascular endothelial cells. EDN1 gene transcrip-
tion produces pre-pro endothelin-1 which is cleaved to big endothelin-1 and then endothelin-1. Endothelin-1 is largely secreted abluminally where
binding to endothelin-A and endothelin-B receptors on vascular smooth muscle cells causes vasoconstriction. Endothelin-B receptor activation on
endothelial cells results in the release of prostacyclin and NO and consequently vasodilatation. Macrophages express both endothelin-A and endo-
thelin-B receptors and display chemokinesis towards endothelin-1. However, endothelin-1 does not polarize M/ to a pro-inflammatory or anti-in-
flammatory phenotype. Our data suggest that M/ clear endothelin-1 through endothelin-B receptor-mediated uptake. Binding of endothelin-1 to
endothelin-B receptor on M/ results in dynamin-dependent endocytosis. This endothelin-B receptor bound endothelin-1 is then transported to the
lysosomes for degradation.
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Take home ﬁgure A novel role for myeloid endothelin-B receptors in hypertension.
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Additionally, this system may partially (16–20%) deplete dendritic
cells (DCs),36 an effect that is more pronounced in the CD11b-DTR
mice.35
Both CD11b-DTR mice administered DT and LysMETB
-/- mice
were more sensitive to the pressor effects of ET-1. Taken together it
is likely these effects were due to an absence of circulating mono-
cytes and/or vascular M/. Given the acute nature of the response,
we hypothesize that in control mice circulating monocytes remove
the intravenously administered ET-1 to some extent thus attenuating
the amount reaching the target VSMC. In contrast, the absence of
this ET-1 clearance in M/-deplete mice allows more to be available
to act on these cells promoting an exaggerated vasoconstrictor and
so hypertensive response. There may be a contribution from DCs
and neutrophils to these effects. Although there is currently no evi-
dence that murine or human DCs are able to regulate ET-1, by its
clearance or degradation, one study has shown that DCs are able to
synthesize ET-1 in response to inflammatory stimuli37 although an-
other has suggested the opposite.38 Interestingly, the few data on
neutrophils and ET-1 suggest that these cells can both produce and
degrade ET-1.39
Our data also demonstrate that M/ are important in hypertension.
We used three models of hypertension—chronic ET-1 and ANG II
infusion, which are both dependent on the ET system,20,21,40,41 and a
high salt diet. M/ depletion with repeated doses of DT resulted in
gradual increases in both systolic and diastolic BP in chronic ET-1 and
salt-dependent hypertension. Interestingly, once the DT administra-
tion was stopped (and M/ were allowed to repopulate) as well as
monocyte adoptive transfer resulted in both systolic and diastolic BP
returning to pre-depletion levels. This suggests that the importance
of both circulating and/or organ-based M/ and future work should
focus on discriminating which of these is more important here. The
importance of the ETB receptor in chronic hypertension is provided
by data from our mice genetically deficient for ETB on M/ alone.
Here, two separate models of hypertension, chronic ET-1 and chron-
ic ANG II infusion, elicited exaggerated rises in both systolic and dia-
stolic BP in knockout animals compared with littermate controls.
ET-1 is considered to be pro-inflammatory, so it was surprising
that it was unable to polarize M/ phenotype, at least in vitro. This was
true at a range of ET-1 concentrations (10–10 000 pg/mL; mean
plasma ET-1 in mice 2–3 pg/mL42), whether the ET-1 was adminis-
tered prior to, following or concomitantly with classical (LPS/INFc)
or alternative (IL-4/IL-13) stimulation. The few data supporting a pro-
inflammatory effect of ET-1 on M/ used immortalized M/ tumour
cell lines and lacked robust methodology.43,44 Interestingly, and in
keeping with earlier studies,37,45 LPS/INFc stimulation of mouse M/
did increase ET-1 concentrations in the supernatant at 24 h and
this was completely blocked by an inhibitor of ECE suggesting that
this increase in immunoreactive ET-1 is a result of de novo production
by M/.
Mouse BMDM demonstrated chemokinesis towards ET-1 and this
was reduced by selective ETA antagonism and completely abrogated
by selective ETB blockade. Two recent studies support our find-
ings46,47 but both found that the ability of M/ to move towards ET-1
was more dependent on the ETA receptor than the ETB. Of note,
both studies investigated that the role of M/ and the ET system in
the setting of cancer (bladder and breast) where there may well be
several different M/ phenotypes with a different balance of ETA:ETB
receptors. In support of ETB-mediated chemokinesis, BMDM from
LysMETB
-/- displayed no migration towards ET-1. This was not due to
an inability to move as they retained their chemokinetic response to
MCP-1. Our data showing that M/ produce ET-1 in response to an
inflammatory stimulus allows us to postulate that this may in turn
lead to recruitment of further M/ to the area of inflammation as a
mechanism to propagate or regulate the response of the innate im-
mune system.
Thus, although M/ are not activated by ET-1 they migrate towards
it and clear the peptide through ETB receptor-mediated uptake pro-
viding a novel clearance mechanism for the peptide. In EC, the ETB
receptor resides within caveolae. Binding of ET-1 to endothelial ETB
stimulates rapid budding and internalization of the caveolae contain-
ing the ETB receptor bound ET-1.
48 This mechanism is dynamin-
dependent. In our in vitro studies, both mouse and human M/
removed ET-1 from their surrounding media, an effect that was sig-
nificantly reduced by selective antagonism (or knockdown) of the
ETB receptor but unaffected by ETA blockade. In keeping with ET-1
clearance by caveolar ETB receptors, inhibiting dynamin GTPase ac-
tivity with dynasore completely prevented ET-1 removal by M/. M/
are multi-functional cells and are able to degrade peptides through
the secretion of proteases as well as through the activity of the cell
surface metalloprotease, NEP.49 However, broad protease and NEP
inhibition did not affect M/ ET-1 uptake.
To demonstrate the clinical relevance of our findings, we studied
patients with ANCA-associated vasculitis, a potentially life-
threatening autoimmune condition. Circulating ET-1 was higher in
those with vasculitis than in health, probably contributed to by sys-
temic inflammation and endothelial dysfunction. Both MMF and CYC
are standard therapies for this condition but they differ in their mech-
anisms of action. Whereas, MMF inhibits T- and B-cell proliferation
and function,50 CYC is directly cytotoxic and depletes not only these
cells but also circulating and tissue M/.28 In keeping with this action,
we demonstrate that CYC has a tendency to reduce the circulating
monocyte count by approximately 50% whereas MMF does not.
Although this is an accepted measure of circulating monocytes51 it
does not account for tissue-based M/. Nevertheless, we show here
that those patients receiving CYC have a greater increase in BP and
deterioration in endothelial function than those receiving MMF. In
part, this may be due to loss of M/-ET regulation. This is supported
by the greater fall in plasma ET-1 in the MMF, but not CYC group,
and the down-regulation of the M/ ETB receptor with CYC but not
MMF. Thus, hypertension in CYC-treated patients may respond well
to ET antagonists. This hypothesis should be explored in future clinic-
al studies as there are few data that relate to the impact of vasculitis
and its treatment on BP or vascular function—which is important be-
cause ET antagonism may have broader cardiovascular benefits.52–55
In summary, our study has identified a new interaction between
M/ and the endothelin system, whereby M/ are drawn to ET-1,
without any evident effect on polarization of phenotype, and clear
ET-1 from the surrounding milieu. In vivo, this cellular action has a sig-
nificant impact on acute vascular function and BP; importantly this
pathway exerts a restraining effect on BP in chronic hypertension.
Our final study strongly suggests that this system is operational in
humans and therefore represents an intriguing opportunity to modu-
late BP and reduce cardiovascular risk in multi-system inflammatory
conditions. In future, studies such as ours might lead to newer and
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.
currently available BP lowering treatments being used in a more ra-
tional way for specific groups of patients, such as those with cancer,
as outlined in recent guidelines.56
Supplementary material
Supplementary material is available at European Heart Journal online.
Acknowledgements
The authors would like to thank Anthony Davenport for the antisera
against the endothelin-A and endothelin-B receptors.
Funding
This work was supported by the British Heart Foundation [FS/11/78/
29328; FS/13/30/29994; FS/16/54/32730], Kidney Research UK [IN10/
2010], and the Institut National de Sante´ et de la Recherche Me´dicale
(INSERM) and research grant from the European Research Council under
the European Union’s Seventh Framework Programme (FP7/2007-2013)/
ERC grant agreement no 107037 (to Dr. Tharaux).
Conflict of interest: none declared.
References
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of
usual blood pressure to vascular mortality: a meta-analysis of individual data for
one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global bur-
den of hypertension: analysis of worldwide data. Lancet 2005;365:217–223.
3. Verlohren S, Muller DN, Luft FC, Dechend R. Immunology in hypertension, pre-
eclampsia, and target-organ damage. Hypertension 2009;54:439–443.
4. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and suben-
dothelial monocyte macrophages in hypertension. Effect of angiotensin convert-
ing enzyme inhibition. Hypertension 1991;18:132–141.
5. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, Rodriguez-
Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune
cells are correlated with blood pressure levels in salt-sensitive hypertension. Am
J Physiol 2007;293:R251–R256.
6. Rodriguez-Iturbe B, Vaziri ND, Johnson RJ. Inflammation, angiotensin II, and
hypertension. Hypertension 2008;52:e135; author reply e136.
7. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park
JK, Beck FX, Muller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H,
van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D,
Titze J. Macrophages regulate salt-dependent volume and blood pressure by a
vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med
2009;15:545–552.
8. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S,
Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H,
Becker C, Daiber A, Waisman A, Munzel T. Lysozyme M-positive monocytes
mediate angiotensin II-induced arterial hypertension and vascular dysfunction.
Circulation 2011;124:1370–1381.
9. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL,
Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux PL, Ruiz P. A role for
angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis
of angiotensin II-dependent hypertension. Hypertension 2010;55:99–108.
10. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of
mineralocorticoid receptors from macrophages protects against
deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure.
Hypertension 2009;54:537–543.
11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki
Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascu-
lar endothelial cells. Nature 1988;332:411–415.
12. Boesen EI, Sasser JM, Saleh MA, Potter WA, Woods M, Warner TD, Pollock JS,
Pollock DM. Interleukin-1beta, but not interleukin-6, enhances renal and system-
ic endothelin production in vivo. Am J Physiol 2008;295:F446–F453.
13. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascu-
lar disease. Biochem Pharmacol 2009;78:539–552.
14. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a
cDNA encoding an endothelin receptor. Nature 1990;348:730–732.
15. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T.
Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothe-
lin receptor. Nature 1990;348:732–735.
16. Davenport AP, O’Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR,
Ferro A. Human endothelin receptors characterized using reverse transcriptase-
polymerase chain reaction, in situ hybridization, and subtype-selective ligands
BQ123 and BQ3020: evidence for expression of ETB receptors in human vascu-
lar smooth muscle. J Cardiovasc Pharmacol 1993;22:S22–S25.
17. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ,
Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenu-
ated by inhibition of nitric oxide synthesis and by endothelin-B receptor block-
ade. Circulation 1998;97:752–756.
18. Newby DE, Strachan FE, Webb DJ. Abnormal endothelin B receptor vasomotor
responses in patients with Hirschprung’s disease. QJM 2002;95:159–163.
19. Schiffrin EL. State-of-the-Art lecture. Role of endothelin-1 in hypertension.
Hypertension 1999;34:876–881.
20. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A,
Harrison DG. Role for endothelin-1 in angiotensin II-mediated hypertension.
Hypertension 1997;30:29–34.
21. Moreau P, d’Uscio LV, Shaw S, Takase H, Barton M, Lu¨Scher TF. Angiotensin II
increases tissue endothelin and induces vascular hypertrophy. Reversal by ETA-
receptor antagonist. Circulation 1997;96:1593–1597.
22. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an
endothelin-receptor antagonist, bosentan, on blood pressure in patients with es-
sential hypertension. N Engl J Med 1998;338:784–790.
23. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antag-
onist for treatment of hypertension. Am J Hypertens 2002;15:583–589.
24. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens
BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to re-
duce blood pressure in patients with treatment-resistant hypertension: a rando-
mised, double-blind, placebo-controlled trial. Lancet 2009;374:1423–1431.
25. Boesen EI, Krishnan KR, Pollock JS, Pollock DM. ETA activation mediates angio-
tensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol 2011;22:
2187–2192.
26. Tostes RC, Touyz RM, He G, Ammarguellat F, Schiffrin EL. Endothelin A recep-
tor blockade decreases expression of growth factors and collagen and improves
matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously
hypertensive rats. J Cardiovasc Pharmacol 2002;39:892–900.
27. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK,
Pollock JS. Endothelin A receptor blockade reduces diabetic renal injury via an
anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143–154.
28. Santosuosso M, Divangahi M, Zganiacz A, Xing Z. Reduced tissue macrophage
population in the lung by anticancer agent cyclophosphamide: restoration by
local granulocyte macrophage-colony-stimulating factor gene transfer. Blood
2002;99:1246–1252.
29. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin
EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and
vascular injury. Hypertension 2011;57:469–476.
30. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M,
Howell DN, Gomez JA, Spurney RF, Coffman TM, Crowley SD. A novel role for
type 1 angiotensin receptors on T lymphocytes to limit target organ damage in
hypertension. Circ Res 2012;110:1604–1617.
31. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J,
Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II
induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449–2460.
32. Javeshghani D, Barhoumi T, Idris-Khodja N, Paradis P, Schiffrin EL. Reduced
macrophage-dependent inflammation improves endothelin-1-induced vascular in-
jury. Hypertension 2013;62:112–117.
33. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in
the molecular age. Nat Rev Immunol 2011;11:788–798.
34. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S,
Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing
roles during liver injury and repair. J Clin Invest 2005;115:56–65.
35. Ferenbach DA, Sheldrake TA, Dhaliwal K, Kipari TM, Marson LP, Kluth DC,
Hughes J. Macrophage/monocyte depletion by clodronate, but not diphtheria toxin,
improves renal ischemia/reperfusion injury in mice. Kidney Int 2012;82:928–933.
36. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene tar-
geting in macrophages and granulocytes using LysMcre mice. Transgen Res 1999;
8:265–277.
37. Spirig R, Potapova I, Shaw-Boden J, Tsui J, Rieben R, Shaw SG. TLR2 and TLR4
agonists induce production of the vasoactive peptide endothelin-1 by human
dendritic cells. Mol Immunol 2009;46:3178–3182.
38. Slobodin G, Pavlotzky E, Panov J, Rosner I, Kessel A, Toubi E. Endothelin-1 does
not change the function of monocyte-derived dendritic cells grown from patients
with systemic sclerosis. Immunol Invest 2008;37:841–848.
Myeloid endothelin-B receptors in hypertension 17
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy881/5289586 by Edinburgh U
niversity user on 17 January 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..39. Sessa WC, Kaw S, Zembowicz A, Anggard E, Hecker M, Vane JR. Human poly-
morphonuclear leukocytes generate and degrade endothelin-1 by two distinct
neutral proteases. J Cardiovasc Pharmacol 1991;17:S34–S38.
40. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition
attenuates oxidative stress but not hypertension produced by chronic ET-1.
Hypertension 2005;45:283–287.
41. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases
glomerular permeability and inflammation independent of blood pressure in the
rat. Hypertension 2010;56:942–949.
42. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M,
Webb DJ, Kotelevtsev YV. Deletion of endothelial cell endothelin B receptors does
not affect blood pressure or sensitivity to salt. Hypertension 2006;48:286–293.
43. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour
necrosis factor in macrophages: ET-receptors, signal transduction and inhibition
by dexamethasone. J Physiol Pharmacol 1997;48:675–688.
44. Wilson SH, Simari RD, Lerman A. The effect of endothelin-1 on nuclear factor
kappa B in macrophages. Biochem Biophys Res Commun 2001;286:968–972.
45. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD,
Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive proper-
ties, are produced by human macrophages. J Exp Med 1990;172:1741–1748.
46. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1
enhances metastatic colonization of the lung in mouse xenograft models of blad-
der cancer. J Clin Invest 2011;121:132–147.
47. Chen CC, Chen LL, Hsu YT, Liu KJ, Fan CS, Huang TS. The endothelin-integrin
axis is involved in macrophage-induced breast cancer cell chemotactic interac-
tions with endothelial cells. J Biol Chem 2014;289:10029–10044.
48. Oh P, Horner T, Witkiewicz H, Schnitzer JE. Endothelin induces rapid, dynamin-
mediated budding of endothelial caveolae rich in ET-B. J Biol Chem 2012;287:
17353–17362.
49. Schreiter A, Gore C, Labuz D, Fournie-Zaluski MC, Roques BP, Stein C,
Machelska H. Pain inhibition by blocking leukocytic and neuronal opioid pepti-
dases in peripheral inflamed tissue. FASEB J 2012;26:5161–5171.
50. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monitor
1995;17:681–684.
51. Barr LC, Brittan M, Morris AC, McAuley DF, McCormack C, Fletcher AM,
Richardson H, Connell M, Patel D, Wallace WA, Rossi AG, Davidson DJ,
Manson L, Turner M, Hirani N, Walsh TS, Anderson NH, Dhaliwal K, Simpson
AJ. A randomized controlled trial of peripheral blood mononuclear cell depletion
in experimental human lung inflammation. Am J Resp Crit Care Med 2013;188:
449–455.
52. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of
endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008;52:452–459.
53. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in
chronic kidney disease. J Am Soc Nephrol 2006;17:943–955.
54. Dhaun N, Johnston NR, Goddard J, Webb DJ. Chronic selective endothelin a re-
ceptor antagonism reduces serum uric Acid in hypertensive chronic kidney dis-
ease. Hypertension 2011;58:e11–e12.
55. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J,
Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria,
blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
Hypertension 2011;57:772–779.
56. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M,
Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F,
Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S,
Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E,
Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018
ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J
2018;39:3021–3104.
18 A. Czopek et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy881/5289586 by Edinburgh U
niversity user on 17 January 2019
